{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:58:15Z","timestamp":1794545895111,"version":"4.9.1"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ChadTough Defeat DIPG Foundation"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["2T32AI007413"],"award-info":[{"award-number":["2T32AI007413"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK094775"],"award-info":[{"award-number":["T32DK094775"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA237421"],"award-info":[{"award-number":["R37CA237421"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is characterized by profound metabolic rewiring and a strongly immunosuppressive tumor microenvironment, both of which contribute to poor therapeutic responses. Immunogenic cell death (ICD) represents a potential strategy to overcome immune suppression by coupling tumor cell death to anti-tumor immune activation. Here, we investigated whether targeting amino acid metabolism in PDAC can induce ICD and promote tumor immunity. Through a focused metabolic screen in a panel of syngeneic mouse cancer cell lines, we identified cysteine restriction as a robust inducer of multiple damage-associated molecular patterns (DAMPs) in vitro, hallmark features of ICD. In addition to driving DAMPs, cystine-deprived tumor cells also promoted dendritic cell phagocytosis, maturation, and proinflammatory cytokine production in vitro. Because cysteine deprivation is a known trigger of ferroptosis, we further demonstrated that pharmacologic inhibition of glutathione peroxidase 4 (GPX4) similarly elicited ICD-associated features, which were reversible by the ferroptosis inhibitor Ferrostatin-1 (Fer-1). To define additional immune-modulatory signals associated with ferroptosis, we performed metabolomic and lipidomic profiling of cells undergoing, but not yet committed to, ferroptotic death. These analyses revealed selective release of immunosuppressive metabolites and oxidized phospholipids. Consistent with this, conditioned media from ferroptotic cells impaired CD8\u207a T cell proliferation and cytotoxicity in vitro. Thus, together our results indicated that the induction of ferroptotic immunogenic cell death led to the release of both pro- and anti-inflammatory signals. Subsequent analysis in vivo revealed that ferroptotic tumor cells predominantly contributed to a tumor-protective environment. In particular, tumors inoculated with ferroptotic cells were enriched with immunosuppressive myeloid cells and exhibited reduced populations of tumor-infiltrating CD8\n                    <jats:sup>+<\/jats:sup>\n                    \u2009T cells. Further investigation using immune compromised mice suggested that ferroptotic cells may suppress both adaptive and innate immune responses. Collectively, these results underscore the complex and highly context-dependent effects of ferroptosis on tumor immunity, highlighting the critical importance of in vivo models to determine true immunogenic potential within the tumor microenvironment.\n                  <\/jats:p>","DOI":"10.1186\/s40170-026-00428-3","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:32:24Z","timestamp":1775298744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Nneka E.","family":"Mbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa E.","family":"Menjivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Giza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sajjakulnukit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeribe C.","family":"Nwosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Alektiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Andren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard C.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pasca di Magliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatrik M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas A.","family":"Lyssiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10:10\u201327.","journal-title":"World J Oncol"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","volume":"28","author":"I Ilic","year":"2022","unstructured":"Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28:4698\u2013715.","journal-title":"World J Gastroenterol"},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: Pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163:386\u2013e4021.","journal-title":"Gastroenterology"},{"key":"428_CR4","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, di Pasca M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"1287459","DOI":"10.3389\/fimmu.2024.1287459","volume":"15","author":"C Hartupee","year":"2024","unstructured":"Hartupee C, et al. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024;15:1287459.","journal-title":"Front Immunol"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"e2400050","DOI":"10.1200\/OA-24-00050","volume":"1","author":"JM Finan","year":"2024","unstructured":"Finan JM, Guo Y, Goodyear SM, Brody JR. Challenges and opportunities in targeting the complex pancreatic tumor microenvironment. JCO Oncol Adv. 2024;1:e2400050.","journal-title":"JCO Oncol Adv"},{"key":"428_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12:173\u201381.","journal-title":"World J Gastrointest Oncol"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457\u201361.","journal-title":"Science"},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21:3561\u20138.","journal-title":"Clin Cancer Res"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son J, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101\u20135.","journal-title":"Nature"},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656\u201370.","journal-title":"Cell"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628\u201332.","journal-title":"Nature"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnaci\u00f3n-Rosado","year":"2021","unstructured":"Encarnaci\u00f3n-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol. 2021;18:482\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","volume":"27","author":"CA Lyssiotis","year":"2017","unstructured":"Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27:863\u201375.","journal-title":"Trends Cell Biol"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccell.2016.12.006","volume":"31","author":"CJ Halbrook","year":"2017","unstructured":"Halbrook CJ, Lyssiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell. 2017;31:5\u201319.","journal-title":"Cancer Cell"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41586-019-1832-9","volume":"576","author":"CR Amendola","year":"2019","unstructured":"Amendola CR, et al. KRAS4A directly regulates hexokinase 1. Nature. 2019;576:482\u20136.","journal-title":"Nature"},{"key":"428_CR18","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1038\/s41467-018-07472-8","volume":"9","author":"N Santana-Codina","year":"2018","unstructured":"Santana-Codina N, et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun. 2018;9:4945.","journal-title":"Nat Commun"},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso C, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633\u20137.","journal-title":"Nature"},{"key":"428_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature19084","volume":"536","author":"CM Sousa","year":"2016","unstructured":"Sousa CM, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536:479\u201383.","journal-title":"Nature"},{"key":"428_CR21","first-page":"6","volume":"6","author":"K-Y Li","year":"2020","unstructured":"Li K-Y, et al. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chronic Dis Transl Med. 2020;6:6\u201317.","journal-title":"Chronic Dis Transl Med"},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.15698\/cst2019.12.205","volume":"3","author":"J-T Li","year":"2019","unstructured":"Li J-T, Wang Y-P, Yin M, Lei Q-Y. Metabolism remodeling in pancreatic ductal adenocarcinoma. Cell Stress. 2019;3:361\u20138.","journal-title":"Cell Stress"},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/ijms21197307","volume":"21","author":"M Huber","year":"2020","unstructured":"Huber M, et al. The Immune Microenvironment in Pancreatic Cancer. Int J Mol Sci. 2020;21:7307.","journal-title":"Int J Mol Sci"},{"key":"428_CR25","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.3390\/cancers13164138","volume":"13","author":"FEF Timmer","year":"2021","unstructured":"Timmer FEF, et al. Pancreatic cancer and immunotherapy: A clinical overview. Cancers (Basel). 2021;13:4138.","journal-title":"Cancers (Basel)"},{"key":"428_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8:199.","journal-title":"NPJ Precis Oncol"},{"key":"428_CR27","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","volume":"15","author":"M Baretti","year":"2024","unstructured":"Baretti M, et al. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nat Commun. 2024;15:9801.","journal-title":"Nat Commun"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","volume":"24","author":"EF Giurini","year":"2025","unstructured":"Giurini EF, Ralph O, Pappas SG, Gupta KH. Looking beyond checkpoint inhibitor monotherapy: Uncovering new frontiers for pancreatic cancer immunotherapy. Mol Cancer Ther. 2025;24:18\u201332.","journal-title":"Mol Cancer Ther"},{"key":"428_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","volume":"15","author":"WL Hwang","year":"2018","unstructured":"Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15:477\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"428_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313\u201322.","journal-title":"Nat Rev Cancer"},{"key":"428_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.ircmb.2016.09.003","volume":"330","author":"I Truxova","year":"2017","unstructured":"Truxova I, et al. Rationale for the combination of dendritic cell-based vaccination approaches with chemotherapy agents. Int Rev Cell Mol Biol. 2017;330:115\u201356.","journal-title":"Int Rev Cell Mol Biol"},{"key":"428_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2017.376","volume":"118","author":"JS Brown","year":"2018","unstructured":"Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2018;118:312\u201324.","journal-title":"Br J Cancer"},{"key":"428_CR35","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"428_CR36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920\u20138.","journal-title":"Nat Med"},{"key":"428_CR37","doi-asserted-by":"publisher","first-page":"1721810","DOI":"10.1080\/2162402X.2020.1721810","volume":"9","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Buqu\u00e9 A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9:1721810.","journal-title":"Oncoimmunology"},{"key":"428_CR38","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","volume":"10","author":"P Liu","year":"2019","unstructured":"Liu P, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10:1486.","journal-title":"Nat Commun"},{"key":"428_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16.","journal-title":"J Immunother Cancer"},{"key":"428_CR40","doi-asserted-by":"crossref","unstructured":"Demuynck R, Efimova I, Naessens F, Krysko DV. Immunogenic ferroptosis and where to find it? J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2021-003430"},{"key":"428_CR41","doi-asserted-by":"crossref","unstructured":"Galluzzi L et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"428_CR42","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp O, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.","journal-title":"Oncoimmunology"},{"key":"428_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375.","journal-title":"Nat Rev Cancer"},{"key":"428_CR44","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","volume":"11","author":"K Hayashi","year":"2020","unstructured":"Hayashi K, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020;11:6299.","journal-title":"Nat Commun"},{"key":"428_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","volume":"24","author":"P Meier","year":"2024","unstructured":"Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24:299\u2013315.","journal-title":"Nat Rev Cancer"},{"key":"428_CR46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"key":"428_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41419-022-04912-8","volume":"13","author":"T Iulianna","year":"2022","unstructured":"Iulianna T, Kuldeep N, Eric F. The Achilles\u2019 heel of cancer: targeting tumors via lysosome-induced immunogenic cell death. Cell Death Dis. 2022;13:509.","journal-title":"Cell Death Dis"},{"key":"428_CR48","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"428_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"428_CR50","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/emboj.2011.497","volume":"31","author":"AD Garg","year":"2012","unstructured":"Garg AD, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31:1062\u201379.","journal-title":"EMBO J"},{"key":"428_CR51","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","volume":"15","author":"J Zindel","year":"2020","unstructured":"Zindel J, Kubes P, DAMPs. PAMPs, and LAMPs in Immunity and Sterile Inflammation. Annu Rev Pathol. 2020;15:493\u2013518.","journal-title":"Annu Rev Pathol"},{"key":"428_CR52","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.","journal-title":"Cell Death Dis"},{"key":"428_CR53","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013\u201321.","journal-title":"Science"},{"key":"428_CR54","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/JCI131859","volume":"130","author":"M-H Oh","year":"2020","unstructured":"Oh M-H, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020;130:3865\u201384.","journal-title":"J Clin Invest"},{"key":"428_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","volume":"5","author":"J Encarnaci\u00f3n-Rosado","year":"2023","unstructured":"Encarnaci\u00f3n-Rosado J, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat Cancer. 2023;5:85\u201399.","journal-title":"Nat Cancer"},{"key":"428_CR56","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/biomedicines13040950","volume":"13","author":"J Jiang","year":"2025","unstructured":"Jiang J, Yan Y, Yang C, Cai H. Immunogenic cell death and metabolic reprogramming in cancer: Mechanisms, synergies, and innovative therapeutic strategies. Biomedicines. 2025;13:950.","journal-title":"Biomedicines"},{"key":"428_CR57","doi-asserted-by":"publisher","first-page":"101234","DOI":"10.1016\/j.xcrm.2023.101234","volume":"4","author":"R Tang","year":"2023","unstructured":"Tang R, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Rep Med. 2023;4:101234.","journal-title":"Cell Rep Med"},{"key":"428_CR58","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","volume":"8","author":"J Lu","year":"2017","unstructured":"Lu J, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8:1811.","journal-title":"Nat Commun"},{"key":"428_CR59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L. Vanpouille-Box, C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"428_CR60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim R, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612:338\u201346.","journal-title":"Nature"},{"key":"428_CR61","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun. 2022;13:3676.","journal-title":"Nat Commun"},{"key":"428_CR62","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8\u2009+\u2009T cells in tumors. Immunity. 2021;54:1561\u2013e15777.","journal-title":"Immunity"},{"key":"428_CR63","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, et al. CD36-mediated ferroptosis dampens intratumoral CD8\u2009+\u2009T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001\u2013e10125.","journal-title":"Cell Metab"},{"key":"428_CR64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj SF, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324\u201338.","journal-title":"Cell"},{"key":"428_CR65","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437\u201350.","journal-title":"Cancer Cell"},{"key":"428_CR66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, et al. Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124\u201336.","journal-title":"Gut"},{"key":"428_CR67","doi-asserted-by":"publisher","first-page":"e49707","DOI":"10.1371\/journal.pone.0049707","volume":"7","author":"MA Collins","year":"2012","unstructured":"Collins MA, et al. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE. 2012;7:e49707.","journal-title":"PLoS ONE"},{"key":"428_CR68","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-15-1032","volume":"6","author":"KB Long","year":"2016","unstructured":"Long KB, et al. IFN\u03b3 and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 2016;6:400\u201313.","journal-title":"Cancer Discov"},{"key":"428_CR69","first-page":"2434","volume":"35","author":"TH Corbett","year":"1975","unstructured":"Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM. Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434\u20139.","journal-title":"Cancer Res"},{"key":"428_CR70","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"428_CR71","doi-asserted-by":"publisher","first-page":"e73245","DOI":"10.7554\/eLife.73245","volume":"11","author":"SA Kerk","year":"2022","unstructured":"Kerk SA, et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife. 2022;11:e73245.","journal-title":"Elife"},{"key":"428_CR72","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang Z, et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 2024;52:W398\u2013406.","journal-title":"Nucleic Acids Res"},{"key":"428_CR73","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","volume":"1","author":"NG Steele","year":"2020","unstructured":"Steele NG, et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat Cancer. 2020;1:1097\u2013112.","journal-title":"Nat Cancer"},{"key":"428_CR74","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.4049\/jimmunol.175.3.1373","volume":"175","author":"M Rossi","year":"2005","unstructured":"Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005;175:1373\u201381.","journal-title":"J Immunol"},{"key":"428_CR75","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/s41423-021-00726-4","volume":"18","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang X, Cheng Y, Cao X. Dendritic cell migration in inflammation and immunity. Cell Mol Immunol. 2021;18:2461\u201371.","journal-title":"Cell Mol Immunol"},{"key":"428_CR76","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1084\/jem.188.7.1359","volume":"188","author":"ML Albert","year":"1998","unstructured":"Albert ML, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359\u201368.","journal-title":"J Exp Med"},{"key":"428_CR77","doi-asserted-by":"crossref","unstructured":"Platt CD, et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci USA. 2010;107:4287\u20134292.","DOI":"10.1073\/pnas.0910609107"},{"key":"428_CR78","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1039\/C9RA00818G","volume":"9","author":"MK Kim","year":"2019","unstructured":"Kim MK, Kim J. Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9:11230\u20138.","journal-title":"RSC Adv"},{"key":"428_CR79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12432","volume":"272","author":"A Alloatti","year":"2016","unstructured":"Alloatti A, Kotsias F, Magalhaes JG, Amigorena S. Dendritic cell maturation and cross-presentation: timing matters! Immunol Rev. 2016;272:97\u2013108.","journal-title":"Immunol Rev"},{"key":"428_CR80","doi-asserted-by":"publisher","first-page":"a016873","DOI":"10.1101\/cshperspect.a016873","volume":"5","author":"T ten Broeke","year":"2013","unstructured":"ten Broeke T, Wubbolts R, Stoorvogel W. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harb Perspect Biol. 2013;5:a016873.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"428_CR81","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","volume":"32","author":"J Zheng","year":"2020","unstructured":"Zheng J, Conrad M. The Metabolic Underpinnings of Ferroptosis. Cell Metab. 2020;32:920\u201337.","journal-title":"Cell Metab"},{"key":"428_CR82","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","volume":"82","author":"D Liang","year":"2022","unstructured":"Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022;82:2215\u201327.","journal-title":"Mol Cell"},{"key":"428_CR83","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","volume":"172","author":"I Ingold","year":"2018","unstructured":"Ingold I, et al. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell. 2018;172:409\u2013e42221.","journal-title":"Cell"},{"key":"428_CR84","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586\u201390.","journal-title":"Nature"},{"key":"428_CR85","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41589-020-0613-y","volume":"16","author":"M Soula","year":"2020","unstructured":"Soula M, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol. 2020;16:1351\u201360.","journal-title":"Nat Chem Biol"},{"key":"428_CR86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VAN Kraft","year":"2020","unstructured":"Kraft VAN, et al. GTP Cyclohydrolase 1\/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. ACS Cent Sci. 2020;6:41\u201353.","journal-title":"ACS Cent Sci"},{"key":"428_CR87","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693\u20138.","journal-title":"Nature"},{"key":"428_CR88","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688\u201392.","journal-title":"Nature"},{"key":"428_CR89","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"428_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley MA, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85\u20139.","journal-title":"Science"},{"key":"428_CR91","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"428_CR92","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1535-6108(03)00050-3","volume":"3","author":"S Dolma","year":"2003","unstructured":"Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285\u201396.","journal-title":"Cancer Cell"},{"key":"428_CR93","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","volume":"16","author":"JK Eaton","year":"2020","unstructured":"Eaton JK, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16:497\u2013506.","journal-title":"Nat Chem Biol"},{"key":"428_CR94","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180\u201391.","journal-title":"Nat Cell Biol"},{"key":"428_CR95","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.4049\/jimmunol.158.11.5095","volume":"158","author":"SG Apasov","year":"1997","unstructured":"Apasov SG, Koshiba M, Chused TM, Sitkovsky MV. Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol. 1997;158:5095\u2013105.","journal-title":"J Immunol"},{"key":"428_CR96","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0021-9258(19)40234-2","volume":"265","author":"A Filippini","year":"1990","unstructured":"Filippini A, Taffs RE, Agui T, Sitkovsky MV. Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem. 1990;265:334\u201340.","journal-title":"J Biol Chem"},{"key":"428_CR97","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol. 2016;16:177\u201392.","journal-title":"Nat Rev Immunol"},{"key":"428_CR98","doi-asserted-by":"publisher","first-page":"e108130","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp O, et al. ATP and cancer immunosurveillance. EMBO J. 2021;40:e108130.","journal-title":"EMBO J"},{"key":"428_CR99","doi-asserted-by":"crossref","unstructured":"Vultaggio-Poma V, Sarti AC, Di Virgilio F. Extracellular ATP: a feasible target for cancer therapy. Cells. 2020;9.","DOI":"10.3390\/cells9112496"},{"key":"428_CR100","doi-asserted-by":"crossref","unstructured":"Zahavi D, Hodge JW. Targeting immunosuppressive adenosine signaling: a review of potential immunotherapy combination strategies. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24108871"},{"key":"428_CR101","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg J, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107:1547\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"428_CR102","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","volume":"3","author":"J Bastid","year":"2015","unstructured":"Bastid J, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3:254\u201365.","journal-title":"Cancer Immunol Res"},{"key":"428_CR103","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/j.gastro.2010.05.007","volume":"139","author":"X Sun","year":"2010","unstructured":"Sun X, et al. CD39\/ENTPD1 expression by CD4\u2009+\u2009Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology. 2010;139:1030\u201340.","journal-title":"Gastroenterology"},{"key":"428_CR104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11302-011-9228-9","volume":"7","author":"BM K\u00fcnzli","year":"2011","unstructured":"K\u00fcnzli BM, et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal. 2011;7:231\u201341.","journal-title":"Purinergic Signal"},{"key":"428_CR105","first-page":"129","volume":"6","author":"SF H\u00e4usler","year":"2014","unstructured":"H\u00e4usler SF, et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res. 2014;6:129\u201339.","journal-title":"Am J Transl Res"},{"key":"428_CR106","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u201365.","journal-title":"J Exp Med"},{"key":"428_CR107","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/JCI45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang L, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121:2371\u201382.","journal-title":"J Clin Invest"},{"key":"428_CR108","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127:929\u201341.","journal-title":"J Clin Invest"},{"key":"428_CR109","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1084\/jem.20130249","volume":"210","author":"C Cekic","year":"2013","unstructured":"Cekic C, Sag D, Day Y-J, Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J Exp Med. 2013;210:2693\u2013706.","journal-title":"J Exp Med"},{"key":"428_CR110","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1158\/0008-5472.CAN-13-3581","volume":"74","author":"C Cekic","year":"2014","unstructured":"Cekic C, Linden J. Adenosine A2A receptors intrinsically regulate CD8\u2009+\u2009T cells in the tumor microenvironment. Cancer Res. 2014;74:7239\u201349.","journal-title":"Cancer Res"},{"key":"428_CR111","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3:506\u201317.","journal-title":"Cancer Immunol Res"},{"key":"428_CR112","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/414916a","volume":"414","author":"A Ohta","year":"2001","unstructured":"Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916\u201320.","journal-title":"Nature"},{"key":"428_CR113","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2008-02-136325","volume":"112","author":"SV Novitskiy","year":"2008","unstructured":"Novitskiy SV, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822\u201331.","journal-title":"Blood"},{"key":"428_CR114","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1111\/j.1365-2567.2009.03075.x","volume":"128","author":"C Linnemann","year":"2009","unstructured":"Linnemann C, et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology. 2009;128:e728\u201337.","journal-title":"Immunology"},{"key":"428_CR115","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","volume":"103","author":"A Ohta","year":"2006","unstructured":"Ohta A, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006;103:13132\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"428_CR116","doi-asserted-by":"crossref","unstructured":"Beavis P.A., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73\u2009+\u2009tumors. Proc Natl Acad Sci U S A. 2013;110:14711\u20136.","DOI":"10.1073\/pnas.1308209110"},{"key":"428_CR117","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","volume":"61","author":"AT Waickman","year":"2012","unstructured":"Waickman AT, et al. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother. 2012;61:917\u201326.","journal-title":"Cancer Immunol Immunother"},{"key":"428_CR118","first-page":"172","volume":"4","author":"R Iannone","year":"2014","unstructured":"Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. 2014;4:172\u201381.","journal-title":"Am J Cancer Res"},{"key":"428_CR119","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","volume":"74","author":"D Mittal","year":"2014","unstructured":"Mittal D, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74:3652\u20138.","journal-title":"Cancer Res"},{"key":"428_CR120","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.3868","volume":"21","author":"ID Mascanfroni","year":"2015","unstructured":"Mascanfroni ID, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-\u03b1. Nat Med. 2015;21:638\u201346.","journal-title":"Nat Med"},{"key":"428_CR121","first-page":"2602","volume":"57","author":"J Blay","year":"1997","unstructured":"Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57:2602\u20135.","journal-title":"Cancer Res"},{"key":"428_CR122","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709\u201324.","journal-title":"Nat Rev Cancer"},{"key":"428_CR123","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.nut.2005.03.003","volume":"21","author":"E Holen","year":"2005","unstructured":"Holen E, Bj\u00f8rge OA, Jonsson R. Dietary nucleotides and human immune cells. II. Modulation of PBMC growth and cytokine secretion. Nutrition. 2005;21:1003\u20139.","journal-title":"Nutrition"},{"key":"428_CR124","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"428_CR125","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41589-020-0472-6","volume":"16","author":"Y Zou","year":"2020","unstructured":"Zou Y, et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat Chem Biol. 2020;16:302\u20139.","journal-title":"Nat Chem Biol"},{"key":"428_CR126","doi-asserted-by":"crossref","unstructured":"Yang WS, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA. 2016;113:E4966-75.","DOI":"10.1073\/pnas.1603244113"},{"key":"428_CR127","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"428_CR128","doi-asserted-by":"crossref","unstructured":"Lee J-Y, Kim WK, Bae K-H, Lee SC, Lee E-W. Lipid metabolism ferroptosis. Biology. 2021;10.","DOI":"10.3390\/biology10030184"},{"key":"428_CR129","doi-asserted-by":"crossref","unstructured":"Agmon E, Solon J, Bassereau P, Stockwell B. Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep. 2018;8.","DOI":"10.1038\/s41598-018-23408-0"},{"key":"428_CR130","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41589-022-01249-3","volume":"19","author":"AN von Krusenstiern","year":"2023","unstructured":"von Krusenstiern AN, et al. Identification of essential sites of lipid peroxidation in ferroptosis. Nat Chem Biol. 2023;19:719\u201330.","journal-title":"Nat Chem Biol"},{"key":"428_CR131","doi-asserted-by":"publisher","first-page":"108381","DOI":"10.1016\/j.celrep.2020.108381","volume":"33","author":"D Zhivaki","year":"2020","unstructured":"Zhivaki D, et al. Inflammasomes within hyperactive Murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity. Cell Rep. 2020;33:108381.","journal-title":"Cell Rep"},{"key":"428_CR132","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/cdd.2016.25","volume":"23","author":"L Magtanong","year":"2016","unstructured":"Magtanong L, Ko PJ, Dixon SJ. Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ. 2016;23:1099\u2013109.","journal-title":"Cell Death Differ"},{"key":"428_CR133","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41419-021-03996-y","volume":"12","author":"J Du","year":"2021","unstructured":"Du J, et al. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. Cell Death Dis. 2021;12:705.","journal-title":"Cell Death Dis"},{"key":"428_CR134","first-page":"0300","volume":"7","author":"H Pan","year":"2024","unstructured":"Pan H, et al. A nutrient-deficient microenvironment facilitates ferroptosis resistance via the FAM60A-PPAR axis in pancreatic ductal adenocarcinoma. Res (Wash D C). 2024;7:0300.","journal-title":"Res (Wash D C)"},{"key":"428_CR135","doi-asserted-by":"publisher","first-page":"108767","DOI":"10.1016\/j.celrep.2021.108767","volume":"34","author":"X Song","year":"2021","unstructured":"Song X, et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. Cell Rep. 2021;34:108767.","journal-title":"Cell Rep"},{"key":"428_CR136","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/s41598-024-55050-4","volume":"14","author":"A Suda","year":"2024","unstructured":"Suda A, et al. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Sci Rep. 2024;14:4409.","journal-title":"Sci Rep"},{"key":"428_CR137","doi-asserted-by":"publisher","first-page":"eadg3049","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15:eadg3049.","journal-title":"Sci Transl Med"},{"key":"428_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01517-4","author":"FI Yapici","year":"2025","unstructured":"Yapici FI, et al. An atlas of ferroptosis-induced secretomes. Cell Death Differ. 2025. https:\/\/doi.org\/10.1038\/s41418-025-01517-4.","journal-title":"Cell Death Differ"},{"key":"428_CR139","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell"},{"key":"428_CR140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"428_CR141","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz JR, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161:1527\u201338.","journal-title":"Cell"},{"key":"428_CR142","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, et al. CD8\u2009+\u2009T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270\u20134.","journal-title":"Nature"},{"key":"428_CR143","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, et al. CD8\u2009+\u2009T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40:365\u2013e3786.","journal-title":"Cancer Cell"},{"key":"428_CR144","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang X, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673\u201385.","journal-title":"Cancer Discov"},{"key":"428_CR145","doi-asserted-by":"crossref","unstructured":"Lin H, et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell. 2024;42:2032\u20132044.e6.","DOI":"10.1016\/j.ccell.2024.10.010"},{"key":"428_CR146","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta AK, Li X-Y, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20:739\u201355.","journal-title":"Nat Rev Immunol"},{"key":"428_CR147","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41419-020-03118-0","volume":"11","author":"B Wiernicki","year":"2020","unstructured":"Wiernicki B, et al. Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis. 2020;11:922.","journal-title":"Cell Death Dis"},{"key":"428_CR148","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1182\/blood-2008-11-191429","volume":"114","author":"S Bl\u00fcml","year":"2009","unstructured":"Bl\u00fcml S, et al. Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids. Blood. 2009;114:5481\u20139.","journal-title":"Blood"},{"key":"428_CR149","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4049\/jimmunol.175.1.501","volume":"175","author":"S Bl\u00fcml","year":"2005","unstructured":"Bl\u00fcml S, et al. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol. 2005;175:501\u20138.","journal-title":"J Immunol"},{"key":"428_CR150","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.4049\/jimmunol.1302801","volume":"192","author":"R Ramakrishnan","year":"2014","unstructured":"Ramakrishnan R, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920\u201331.","journal-title":"J Immunol"},{"key":"428_CR151","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber DL, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16:880\u20136.","journal-title":"Nat Med"},{"key":"428_CR152","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18:804\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"428_CR153","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1038\/s41418-019-0299-4","volume":"26","author":"Y Li","year":"2019","unstructured":"Li Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia\/reperfusion. Cell Death Differ. 2019;26:2284\u201399.","journal-title":"Cell Death Differ"},{"key":"428_CR154","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig A-M, Kaech SM, Wherry E. J. CD8\u2009+\u2009T cells in the cancer-immunity cycle. Immunity. 2023;56:2231\u201353.","journal-title":"Immunity"},{"key":"428_CR155","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaut.2017.07.010","volume":"85","author":"A Sica","year":"2017","unstructured":"Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017;85:117\u201325.","journal-title":"J Autoimmun"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-026-00428-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00428-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00428-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:28:44Z","timestamp":1781645324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40170-026-00428-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/s40170-026-00428-3","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved by the University of Michigan Institutional Animal Care and Use Committee following PRO00010606.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.A.L. has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US patent 2015126580-A1, 05\/07\/2015; US patent 20190136238, 05\/09\/2019; international patent WO2013177426-A2, 04\/23\/2015).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}